- Meeting abstract
- Open access
- Published:
New insights on low-grade and T-cell lymphoma
Journal of Hematology & Oncology volume 2, Article number: A3 (2009)
The advances in low-grade lymphoma & T-cell lymphoma from the 2008 ASH meeting were presented. These included therapeutic regimens for low grade lymphoma, frontline bendamustine plus rituximab data, radioimmunotherapy consolidation in advanced disease, idiotype vaccine, and other novel therapeutic agents such as next generation anti-CD20 GA101, syk inhibitor Fostamatinib in treatment of low-grade lymphoma. In T-cell lymphoma, updates were discussed on phase II HOVON 69 trial data of combination of alemtuzumab/CHOP, pralatrexate and romidepsin for relapsed/refractory PTCL, L-asparaginase-containing regimen for extranodal NK/T-cell lymphoma.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Tse, W. New insights on low-grade and T-cell lymphoma. J Hematol Oncol 2 (Suppl 1), A3 (2009). https://doi.org/10.1186/1756-8722-2-S1-A3
Published:
DOI: https://doi.org/10.1186/1756-8722-2-S1-A3